[go: up one dir, main page]

WO2012040444A3 - Treatment of patients with incipient alzheimer's disease - Google Patents

Treatment of patients with incipient alzheimer's disease Download PDF

Info

Publication number
WO2012040444A3
WO2012040444A3 PCT/US2011/052731 US2011052731W WO2012040444A3 WO 2012040444 A3 WO2012040444 A3 WO 2012040444A3 US 2011052731 W US2011052731 W US 2011052731W WO 2012040444 A3 WO2012040444 A3 WO 2012040444A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
disease
treatment
incipient alzheimer
incipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/052731
Other languages
French (fr)
Other versions
WO2012040444A2 (en
Inventor
Charles F. Albright
Robert Mark Berman
Vladimir Coric
Howard Feldman
Ronald N. Marcus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO2012040444A2 publication Critical patent/WO2012040444A2/en
Publication of WO2012040444A3 publication Critical patent/WO2012040444A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are methods for the treatment of patients with incipient Alzheimer's disease and the use of compounds that may be inhibitors of the enzymes that form β -amyloid (A β), e.g., A β 42, in particular γ-secretase.
PCT/US2011/052731 2010-09-24 2011-09-22 Treatment of patients with incipient alzheimer's disease Ceased WO2012040444A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38601410P 2010-09-24 2010-09-24
US61/386,014 2010-09-24

Publications (2)

Publication Number Publication Date
WO2012040444A2 WO2012040444A2 (en) 2012-03-29
WO2012040444A3 true WO2012040444A3 (en) 2012-06-28

Family

ID=45874374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052731 Ceased WO2012040444A2 (en) 2010-09-24 2011-09-22 Treatment of patients with incipient alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2012040444A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
CN105102448B (en) 2013-02-28 2018-03-06 百时美施贵宝公司 Phenylpyrazole derivatives as ROCK1 and ROCK2 inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047671A2 (en) * 2000-11-17 2002-06-20 Eli Lilly And Company Lactam compound to inhibit beta-amyloid peptide release or synthesis
US20020111343A1 (en) * 1996-12-23 2002-08-15 Jing Wu Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
WO2005023772A1 (en) * 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
WO2009008980A2 (en) * 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
WO2009058552A1 (en) * 2007-10-31 2009-05-07 Bristol-Myers Squibb Company A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111343A1 (en) * 1996-12-23 2002-08-15 Jing Wu Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
WO2002047671A2 (en) * 2000-11-17 2002-06-20 Eli Lilly And Company Lactam compound to inhibit beta-amyloid peptide release or synthesis
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
WO2005023772A1 (en) * 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
WO2009008980A2 (en) * 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
WO2009058552A1 (en) * 2007-10-31 2009-05-07 Bristol-Myers Squibb Company A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLENNOW ET AL.: "CSF markers for incipient Alzheimer's disease.", LANCET NEUROL, vol. 2, 2003, pages 605 - 613, XP004811238, DOI: doi:10.1016/S1474-4422(03)00530-1 *
HAMPEL ET AL.: "Biological markers for early detection and pharmacological treatment of Alzheimer's disease.", DIALOGUES CLIN NEUROSCI., vol. 11, 2009, pages 141 - 157 *
LILLY.: "Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials.", PR NEWSWIRE, 17 August 2010 (2010-08-17), pages 1 - 2 *
MANGIALASCHE ET AL.: "Alzheimer's disease: clinical trials and drug development.", LANCET NEUROL, vol. 9, July 2010 (2010-07-01), pages 702 - 716, XP027598946, DOI: doi:10.1016/S1474-4422(10)70119-8 *
SHAW ET AL.: "Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects.", ANN NEUROL, vol. 65, 2009, pages 403 - 413 *

Also Published As

Publication number Publication date
WO2012040444A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2009089494A3 (en) Pharmaceutical compositions
WO2012062925A3 (en) Compounds and methods for treating pain
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
MY172372A (en) Compositions and methods for lowering triglycerides
WO2013057570A3 (en) Acrylic polymer formulations
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
IL223819A0 (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
WO2013003899A8 (en) Methods of treating or preventing rheumatic disease
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
WO2012040444A3 (en) Treatment of patients with incipient alzheimer's disease
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
WO2010129788A3 (en) Uses of cationic hydroxythylcellulose in oral ingestion forms, and prevention and treatment of metabolic disorders
WO2009091932A3 (en) Treatment of mild dementia of the alzheimer's disease type
WO2012051165A3 (en) Mir-211 expression and related pathways in human melanoma
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827523

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11827523

Country of ref document: EP

Kind code of ref document: A2